Cellular Phototoxicity Evoked Through the Inhibition of Human ABC Transporter ABCG2 by Cyclin-dependent Kinase Inhibitors In vitro
- 292 Downloads
The physiological importance of the human ATP-binding cassette (ABC) transporter ABCG2 has been recognized with regard to porphyrin-mediated photosensitivity. Functional impairment owing to inhibition of ABCG2 by drugs or its genetic polymorphisms may lead to the disruption of porphyrin homeostasis, which in turn causes cellular toxicity.
Materials and Methods
We evaluated the impact on photosensitivity of the inhibition by cyclin-dependent kinase (CDK) inhibitors of ABCG2 function. For this purpose, we established new methods for photosensitivity assays by using Flp-In-293 cells and plasma membrane vesicles prepared from Sf9 insect cells. With the new methods, we subsequently tested CDK inhibitors, i.e., purvalanol A, WHI-P180, bohemine, roscovitine, and olomoucine.
Among CDK inhibitors tested, purvalanol A was found to be the most potent inhibitor (IC50 = 3.5 μM) for ABCG2-mediated hematoporphyrin transport. At a concentration of 2.5 μM, it evoked the photosensitivity of ABCG2-expressing Flp-In-293 cells treated with pheophorbide a. WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. In contrast, the phototoxicity of bohemine, roscovitine, and olomoucine were minimal in our assay system.
It is suggested that the planar structure is an important factor for interactions with the active site of ABCG2. The present study provides a new approach to studying drug-induced phototoxicity in vitro.
KEY WORDSABCG2 (BCRP/MXR) cyclin-dependent kinase inhibitor pheophorbide a phototoxicity porphyrin
breast cancer resistance protein
Dulbecco’s modified Eagle’s medium
epidermal growth factor receptor
fetal calf serum
highest occupied molecular orbital
concentration leading to a 50%-inhibition
quantitative structure-activity relationship
This study was supported, in part, by the NEDO International Joint Research Grant program “International standardization of functional analysis technology for genetic polymorphisms of drug transporters” and research grants (No. 18201041 and No. 19659136) from the Japanese Society for the Promotion of Science (JSPS). Ai Tamura and Hikaru Saito are JSPS Research Fellows.
- 1.J. W. Jonker, S. Musters, M. L. Vlaming, T. Plosch, K. E. Gooijert, M. J. Hillebrand, H. Rosing, J. H. Beijnen, H. J. Verkade, and A. H. Schinkel. Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. Am. J. Physiol. Cell. Physiol. 292:C2204–2212 (2007). doi: 10.1152/ajpcell.00359.2006.PubMedCrossRefGoogle Scholar
- 2.J. W. Jonker, M. Buitelaar, E. Wagenaar, M. A. Van Der Valk, G. L. Scheffer, R. J. Scheper, T. Plosch, F. Kuipers, R. P. Elferink, H. Rosing, J. H. Beijnen, and A. H. Schinkel. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U.S.A. 99:15649–15654 (2002). doi: 10.1073/pnas.202607599.PubMedCrossRefGoogle Scholar
- 3.A. Tamura, M. Watanabe, H. Saito, H. Nakagawa, T. Kamachi, I. Okura, and T. Ishikawa. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol. Pharmacol. 70:287–296 (2006).PubMedGoogle Scholar
- 4.A. Tamura, Y. Onishi, R. An, S. Koshiba, K. Wakabayashi, K. Hoshijima, W. Priebe, T. Yoshida, S. Kometani, T. Matsubara, K. Mikuriya, and T. Ishikawa. In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. Drug Metab. Pharmacokinet. 22:428–440 (2007). doi: 10.2133/dmpk.22.428.PubMedCrossRefGoogle Scholar
- 7.K. Miyake, L. Mickley, T. Litman, Z. Zhan, R. Robey, B. Cristensen, M. Brangi, L. Greenberger, M. Dean, T. Fojo, and S. E. Bates. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59:8–13 (1999).PubMedGoogle Scholar
- 9.D. D. Ross, W. Yang, L. V. Abruzzo, W. S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, S. P. Cole, and L. A. Doyle. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 91:429–433 (1999). doi: 10.1093/jnci/91.5.429.PubMedCrossRefGoogle Scholar
- 10.M. Brangi, T. Litman, M. Ciotti, K. Nishiyama, G. Kohlhagen, C. Takimoto, R. Robey, Y. Pommier, T. Fojo, and S. E. Bates. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 59:5938–5946 (1999).PubMedGoogle Scholar
- 11.S. Kawabata, M. Oka, K. Shiozawa, K. Tsukamoto, K. Nakatomi, H. Soda, M. Fukuda, Y. Ikegami, K. Sugahara, Y. Yamada, S. Kamihira, L. A. Doyle, D. D. Ross, and S. Kohno. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. 280:1216–1223 (2001). doi: 10.1006/bbrc.2001.4267.PubMedCrossRefGoogle Scholar
- 12.S. Koshiba, R. An, H. Saito, K. Wakabayashi, A. Tamura, and T. Ishikawa. Human ABC transporters ABCG2 (BCRP) and ABCG4. Xenobiotica 38:863–888(2008).Google Scholar
- 16.V. Brazzelli, F. Prestinari, T. Barbagallo, C. Rona, E. Orlandi, F. Passamonti, F. Locatelli, M. Zecca, S. Villani, and G. Borroni. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J. Eur. Acad. Dermatol. Venereol. 21:384–387 (2007). doi: 10.1111/j.1468-3083.2006.01981.x.PubMedCrossRefGoogle Scholar
- 17.C. Ozvegy-Laczka, T. Hegedus, G. Varady, O. Ujhelly, J. D. Schuetz, A. Varadi, G. Keri, L. Orfi, K. Nemet, and B. Sarkadi. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65:1485–1495 (2004). doi: 10.1124/mol.65.6.1485.PubMedCrossRefGoogle Scholar
- 18.H. Saito, H. Hirano, H. Nakagawa, T. Fukami, K. Oosumi, K. Murakami, H. Kimura, T. Kouchi, M. Konomi, E. Tao, N. Tsujikawa, S. Tarui, M. Nagakura, M. Osumi, and T. Ishikawa. A new strategy of high-speed screening and quantitative structure–activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J. Pharmacol. Exp. Ther. 317:1114–1124 (2006). doi: 10.1124/jpet.105.099036.PubMedCrossRefGoogle Scholar
- 21.P. L. Porter, K. E. Malone, P. J. Heagerty, G. M. Alexander, L. A. Gatti, E. J. Firpo, J. R. Daling, and J. M. Roberts. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:222–225 (1997). doi: 10.1038/nm0297-222.PubMedCrossRefGoogle Scholar
- 23.A. Tamura, K. Wakabayashi, Y. Onishi, H. Nakagawa, M. Tsuji, Y. Matsuda, and T. Ishikawa. Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system. J. Exp. Ther. Oncol. 6:1–11 (2006).PubMedGoogle Scholar
- 24.A. Tamura, K. Wakabayashi, Y. Onishi, M. Takeda, Y. Ikegami, S. Sawada, M. Tsuji, Y. Matsuda, and T. Ishikawa. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci. 98:231–239 (2007). doi: 10.1111/j.1349-7006.2006.00371.x.PubMedCrossRefGoogle Scholar
- 25.K. Wakabayashi, H. Nakagawa, A. Tamura, S. Koshiba, K. Hoshijima, M. Komada, and T. Ishikawa. Intramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 protein. J. Biol. Chem. 282:27841–27846 (2007). doi: 10.1074/jbc.C700133200.PubMedCrossRefGoogle Scholar
- 27.N. B. Elkind, Z. Szentpetery, A. Apati, C. Ozvegy-Laczka, G. Varady, O. Ujhelly, K. Szabo, L. Homolya, A. Varadi, L. Buday, G. Keri, K. Nemet, and B. Sarkadi. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 65:1770–1777 (2005). doi: 10.1158/0008-5472.CAN-04-3303.PubMedCrossRefGoogle Scholar
- 28.D. E. MacCallum, J. Melville, S. Frame, K. Watt, S. Anderson, A. Gianella-Borradori, D. P. Lane, and S. R. Green. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65:5399–5407 (2005). doi: 10.1158/0008-5472.CAN-05-0233.PubMedCrossRefGoogle Scholar
- 29.H. Saito, H. Hirano, and T. Ishikawa. High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance. Mini Rev. Med. Chem. 7:1009–1018 (2007). doi: 10.2174/138955707782110169.PubMedCrossRefGoogle Scholar